iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 [Yahoo! Finance]
iBio, Inc. (IBIO)
NASDAQ:AMEX Investor Relations:
ir.ibioinc.com
Company Research
Source: Yahoo! Finance
associated with HFpEF ( PH-HFpEF ), and expects to declare a development candidate in Q3 while aiming for chronic subcutaneous dosing. Management ties the program to its obesity/TGF-ß work and cites strong external validation of the activin pathway—Merck's sotatercept reported positive CADENCE results in CPCPH/HFpEF and GSK's acquisition of 35Pharma highlights commercial interest in pulmonary hypertension. iBio emphasizes selective blockade that spares BMP9/BMP10 and activin B to limit bleeding/hemodynamic risks and preserve metabolic effects, and its internal cell and rodent HFpEF data show antifibrotic/cardiac benefit signals though human translation is unproven. Interested in iBio, Inc.? Here are five stocks we like better. Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could bec
Show less
Read more
Impact Snapshot
Event Time:
IBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBIO alerts
High impacting iBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBIO
News
- iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.MarketBeat
- iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) [Yahoo! Finance]Yahoo! Finance
- iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewswire
- iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss [Yahoo! Finance]Yahoo! Finance
- iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight LossGlobeNewswire
IBIO
Sec Filings
- 3/9/26 - Form 8-K
- 3/9/26 - Form EFFECT
- 3/6/26 - Form 424B5
- IBIO's page on the SEC website